2026-04-13T16:49:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/59012025-06-22T12:33:52Zcom_2072_378071com_2072_378040col_2072_378097

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study Domínguez, Ángela García-García, Juan José Gonzalez Peris, Sebastia Uriona Tuma, Sonia Maria Codina Grau, Gema Planes Reig, Anna Maria Izquierdo, Conchita Hernández Baeza, Sergi Campins Martí, Magda Soldevila, Núria Moraga Llop, Fernando Ciruela, Pilar Institut Català de la Salut [Domínguez Á, Soldevila N] Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Ciruela P] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain. [Hernández S, Izquierdo C] Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain. [García-García JJ] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Malalties Prevenibles amb vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain. [Moraga-Llop F, González-Peris S, Codina G, Planes AM] Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Campins M, Uriona S] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Epidemiologia i Salut Pública, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Vacuna antipneumocòccica Infeccions per estreptococs Infants DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Streptococcal Infections::Pneumococcal Infections CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Vaccines, Synthetic::Vaccines, Conjugate NAMED GROUPS::Persons::Age Groups::Child::Child, Preschool ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones estreptocócicas::infecciones neumocócicas COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas sintéticas::vacunas conjugadas DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño::niño preescolar Estudis de control de casos; Pneumònia; Vacunació i immunització Estudios de casos y controles; Neumonía; Vacunación e inmunización Case-control studies; Pneumonia; Vaccination and immunization Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effectiveness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children aged 7–59 months in a population with suboptimal vaccination coverage of 55%. Methods The study was carried out in children with IPD admitted to three hospitals in Barcelona (Spain) and controls matched by hospital, age, sex, date of hospitalization and underlying disease. Information on the vaccination status was obtained from written medical records. Conditional logistic regression was made to estimate the adjusted VE and 95% confidence intervals (CI). Results 169 cases and 645 controls were included. The overall VE of ≥1 doses of PCV13 in preventing IPD due to vaccine serotypes was 75.8% (95% CI, 54.1–87.2) and 90% (95% CI, 63.9–97.2) when ≥2 doses before 12 months, two doses on or after 12 months or one dose on or after 24 months, were administered. The VE of ≥1 doses was 89% (95% CI, 42.7–97.9) against serotype 1 and 86.0% (95% CI, 51.2–99.7) against serotype 19A. Serotype 3 showed a non-statistically significant effectiveness (25.9%; 95% CI, -65.3 to 66.8). Conclusions The effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7–59 months was good and, except for serotype 3, the effectiveness of ≥1 doses against the most frequent PCV13 serotypes causing IPD was high when considered individually. This work was supported by the Plan Nacional I+D+I, ISCIII – Subdirección General de Evaluación y Fomento de la Investigación Sanitaria (Projects PI 11/02081, PI 11/2345) and cofounded by Fondo Europeo de Desarrollo Regional (FEDER) and AGAUR (Grant 2014 SGR 1403). 2021-04-22T10:28:10Z 2021-04-22T10:28:10Z 2017-08-14 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Domínguez Á, Ciruela P, Hernández S, García-García JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. Melo-Cristino J, editor. PLoS One. 2017 Aug 14;12(8):e0183191. 1932-6203 https://hdl.handle.net/11351/5901 10.1371/journal.pone.0183191 28806737 000407548800063 eng PLoS ONE;12(8) https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183191 info:eu-repo/grantAgreement/ES/1PN/2008-2011/PI11%2F02081 info:eu-repo/grantAgreement/ES/2PN/2008-2011/PI11%2F02345 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Public Library of Science Scientia